Histocompatibility Testing in Renal Transplantation by Hayashi, Hajime & Hunter, Jay B.
Henry Ford Hospital Medical Journal 
Manuscript 2011 
Histocompatibility Testing in Renal Transplantation 
Hajime Hayashi 
Jay B. Hunter 
Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal 
 Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons 
Henry Ford Hosp Med Journal 
Vol 26, No 3, 1978 
Histocompatibility Testing in Renal Transplantation 
Hajime Hayashi, PhD* and Jay B. Hunter, BS* 
The effect of HLA matching and other aspects of histocom-
patibility on renal graft survival were analyzed in 144 
patients who received renal transplants at Henry Ford 
Hospital during the past ten years. Living related transplants 
with one haplotype match or better demonstrated a higher 
graft survival rate (at least 88%) at one year than the better 
matched cadaveric transplant. In cadaveric transplants, the 
group with fewer tban two mismatched antigens appeared 
to have a higher graft survival rate than those with more than 
two. The patient population was not large enough to 
determine the effect of preformed antibodies, ABO group-
ing, or other recipient factors on graft survival. 
M ORE than ten years ago, human leukocyte (HLA) typing 
was introduced for the prospective matching of donor and 
recipient in organ transplantation. Yet the significance of 
histocompatibility testing is still controversial, even though 
many HLA an t igens ( t issue an t igens) have been 
characterized.^"^ 
HLA antigens are glycoproteins expressed on the surface of 
all nucleated cells of human tissue. These determinants are 
coded by the major histocompatibility complex (MHC) 
located on chromosome 6 at four loci.^ The inheritance of 
HLA antigens is exemplified in Figure 1. In obedience to 
Mendelian law, an individual can receive only two codomi-
nantly expressed antigens for each locus, one from each 
parental haplotype. The HLA-A, -B, -C, -D antigens com-
prise a highly polymorphic system with over 60 well-
defined specificities. Table 1 lists the HLA antigens and 
workshop (W) antigens presently recognized by the W H O 
Nomenclature Committee.^'^^ 
In the laboratory, antibody dependent procedures" identify 
serological determinants (SD) or antigens in HLA-A, -B, -C 
loci. Mixed lymphocyte culture (MLC) distinguishes lym-
phocyte determinants (LD) or antigens in HLA-D locus.'^ 
The mechanisms of recognition in LD are cellular while 
those in SD are humoral. Because the antigens in HLA-A and 
-B loci are more clearly characterized, most transplant 
centers report the data of HLA matching only for these 
antigens. 
Since 1968, histocompatibility testing has been used in 149 
renal transplants performed at Henry Ford Hospital. This is a 
preliminary report of histocompatibility testing and graft 
survival involving these patients. 
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Materials and Methods 
Patients 
The total number of renal transplants (149) at Henry Ford 
Hospital from 1968 to 1977 is summarized in Table II. Of 
these, 126 were cadaveric and 23 were living related. Five 
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Father Mother 
A l , B5, C W I , DWS c A28, 812, CW3, DW7 
A2, B7, CW2, DW6 c A29, B i 3 , CW4, DWS 
1, a 
Offspring 
A l , B5, C W I , DWS 
2." 
0 
a 
A28, 
Al, 
B12, 
B5, 
CW3, 
C W I , 
DW7 
DWS 
3. 
d 
b 
A29, 
A2, 
B13, 
B7, 
CW4, 
CW2, 
owe 
DW6 
4. 
c 
b 
A28, 
A2, 
B12, 
B7, 
CW3, 
CW2, 
DW7 
DW6 
5.' 
ci 
a 
A29, 
A l , 
B13, 
B5, 
CW4, 
C W I , 
DWS 
DWS 
d A29, B13, CW4, DWS 
TABLE I 
NOMENCLATURE FOR FACTORS OFTHE HLA SYSTEMS—1977 
Identical 
Fig.1 
were not included in this study because only crossmatch 
(without HLA typing) was performed. 
HLA typing and crossmatch 
These procedures were carried out by a standard micro-
lymphocytotoxicity method modified from Terasaki.^^ 
Briefly, lymphocytes were separated from heparinized 
blood by either nylon column or Ficol-Hypaque procedures 
(specific gravity: 1.076-1.077) and were adjusted to 1.5-2.0 
million cel ls/ml. 
For HLA typing, two or three micro-trays with a panel of 
known antisera were used. A lymphocyte suspension of 
0.001 ml was added to each well of typing trays containing 
0.001 ml of antiserum and incubated for 30 minutes at room 
temperature, then incubated for an additional 60 minutes 
with 0.05 ml of rabbit complement at room temperature. At 
the end of incubation, 0.005 ml of 5% aqueous eosin was 
added, followed by 0.005 ml of formalin. The lymphocyte 
reaction with antisera was read on an inverted phase 
microscope. 
For crossmatching, the most recent specimen and most 
reactive sera from preformed antibody screening were 
included in the following dilutions made up in duplicate: 
1:1.3 0.003 ml of undiluted serum 
1:2 0.001 ml of undiluted serum 
1:4 0.001 ml of 1:2 diluted serum 
The incubation time of crossmatching was extended to 45 
minutes after the addition of lymphocytes to the patient sera 
Locus A Locus B Locus C Locus D Locus DR 
A l 35 CWI DWI DRW1 
A2 B7 CW2 DW2 DRW2 
A3 88 CW3 DW3 DRW3 
AS 812 CW4 DW4 DRW4 
AID B13 cws DWS DRWS 
A11 B14 CW6 DW6 DRWe 
A2S 81S DW7 DRW7 
A26 817 DWS DRWS 
A28 B18 DW9 
A29 827 DW10 
*AW19 837 DW11 
AW23 B40 
AW24 BW16 
AW30 BW21 
AW31 BW22 
AW32 BW3S 
AW34 BW3S 
AW36 BW39 
AW43 BW41 
BW42 
BW44 
BW4S 
BW46 
8W47 
8W48 
BW49 
BW50 
BWSI 
BWS2 
BW53 
BW54 
BW4 
BW6 
' W (workshop): Antigens in the process of characterization but not 
yet accepted by the WHO committee 
TABLE 
RENAL TRANSPLANTS AT HENRY FORD HOSPITAL 
Cadaveric Living Related 
Year 1st 2nd 3rd 1st 2nd 3rd Total 
1968 1 3 4 
1969 4 0 4 
1970 5 1 2 8 
1971 4 2 0 6 
1972 11 0 11 
1973 6 1 2 9 
1974 18 1 1 20 
197S 25 2 4 31 
1976 21 2 2 25 
1977 14 7 1 6 1 2 31 
Total 109 16 1 20 1 2 149 
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and 90 minutes afterthe addi t ion of rabbit complement . The 
crossmatch between recipient 's sera and donor 's l ympho-
cytes was negative in all cases. For the purpose of this 
analysis, the mismatched antigens in HLA-A and -B loci 
were grouped and compared accordingly. 
Antibody screenings 
These screen ings were per formed against a panel of 20 to 40 
characterized cel Is selected to cover the major i ty of known 
HLA antigens at the t ime of screening. A specimen w i t h 10% 
or greater presensitization against 20 to 40 cells was cons id-
ered posit ive. 
Results 
HLA matching and renal survival rate of 
cadaveric transplants 
Table III shows the renal graft survival rate at 6 and 12 
months of 102 patients w i t h a pr imary cadaveric transplant. 
The overal I survival rate was 4 5 % at 6 months and 38% at 12 
months. The patient group w i t h fewer mismatched antigens 
(two or less) demonstrated a higher survival rate, except 
those w i t h one mismatched antigen at 12 months. A l though 
these numbers are not large, it appears that the more closely 
HLA matched groups demonstrated greater graft survival 
rates. 
TABLE III 
HLA MATCHING AND RENAL GRAFT SURVIVAL 
(First Cadaveric Transplant) 
No. of 
Mismatched Graft Survival 
HLA Antigens 6 Months 12 Months 
0 
1 
2 
3 
4 
% 
1/1 (100) 
s/10 (SO) 
14/23 (61) 
IS/49 (37) 
8/19 (42) 
1/1 
20/34 (59%) 3/9 
12/22 
26/68 (38%) 17/49 
S/18 
(100) 
(33) 
(55) 
(35) 
(28) 
16/32 (S0%) 
22/67 (33%) 
46/102 (4S%) 38/99* (38%) 
* Three ofthe patients had good kidney function but had not reached 
the 12-month follow-up. 
Table IV summarizes the HLA matching and graft survival of 
20 patients receiving a second and third cadaveric trans-
plant. In this small group there is no correlat ion between 
HLA match ing and renal graft survival rates. Even those 
patients w i t h three HLA mismatched antigens showed a 
greater than 60% graft survival rate at 6 and 12 months. 
TABLE IV 
HLA MATCHING AND RENAL GRAFT SURVIVAL 
(Second and Third Cadaveric Transplants) 
No. of Mismatched 
HLA Antigens 
Graft Survival 
6 Months 12 Months 
% % 
0 0/2 (0) 
— 
1 3/4 (7S) 2/3 (67) 
2 1/3 (33) 1/3 (33) 
3 4/6 (67) 3/S (60) 
4 2/5 (40) O/S (0) 
10/20 (S0%) 6/16* (38% 
* Four patients had good kidney function but had not reached the 12-
month follow-up. 
HLA matching and renal graft survival rate of living related 
transplants* 
Table V summarizes the results of a group made up of 
s ibl ing-to-sibl ing or parent-to-chi ld transplants w i t h at least 
one match ing haplotype. Most patients in this group had no 
mismatched antigens. Patients w i t h both first and subse-
quentt ransplants f rom l iv ing related donors demonstrated a 
high graft survival rate (more than 88%). 
TABLE V 
HLA MATCHING AND RENAL GRAFT SURVIVAL 
No. of 
Mismatched 
HLA Antigens 6 Months 12 Months 
Living related 
1st transplant 
Living related 2nd 
and 3rd transplant 
% 
13/14(93) 
4/4 (100) 
0/1 (0) 
% 
11/12 (92) 
4/4 (100) 
0/1 (0) 
17/19 (89.5) 15/17* (88) 
2,'2 
1/1 
(100) 
(100) 
2/2 
1/1 
(100) 
(100) 
3/3 (100) 3/3 (100) 
* Two patients had good kidney function but had not reached the 12-
month follow-up. 
HLA matching in A B O group on renal graft survival rate 
Eighty-nine pairs (donor and recipient) were avai lable for 
A B O group analysis at 12 months (Table VI). There is no 
signif icant di f ference in graft survival of O donor - to -O 
recipient and A donor- to-A recipient. In both groups, the 
value of HLA match ing is evident. For the remain ing 13 
patients w i t h other A B O groups, the number isnot suff icient 
to d raw any conc lus ion. 
* In 1976, the MLC test was added to related donor screening but data are 
insufficient to include in this study. 
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TABLE VI 
HLA MATCHING ABO BLOOD GROUP 
AND RENAL GRAFT SURVIVAL AT 12 MONTHS 
No. of 
Mismatched Donor to Recipient 
HLA Antigens 0-0 A-A 
0 
% % 
1 2/5 (40) 0/2 (0) 
2 7/13(54) 3/6 (SO) 
3 6/19 (32) 6/17 (3S) 
4 1/6 (17) 1/8 (13) 
16/43 (37) 10/33 (30) 
O-A 1 patient 
B-B 10 patients 
8-AB 2 patients 
Preformed antibodies and renal graft survival rate 
In 1974, preformed ant ibody screening was established in 
our laboratory. Seventy-eight patients w i t h a first transplant 
were avai lable for this study (Table Vl l ) . A m o n g these, 13 
demonstrated HLA cytotoxic antibodies before transplanta-
t ion. Seven o f the 13 showed a good graft survival rate (54%) 
in spite o f t h e presence of preformed ant ibodies. 
TABLE Vll 
PREFORMED CYTOTOXIC ANTIBODY 
AND RENAL GRAFT SURVIVAL AT 12 MONTHS 
Graft Survival Rate 
No. of 
Mismatched 
HLA Antigens 
Antibody 
Positive* 
Antibody 
Negative 
0 
1 
2 
3 
4 
% 
1/1 (100) 
4/9 (44) 
2/3 (67) 
% 
1/1 (100) 
1/6 (17) 
10/15 (67) 
11/29 (38) 
3/14 (21) 
7/13(54) 26/65(40) 
* 10% or greater presensitization against 20 to 40 cells 
Antibody screening of dialysis and transplant patients 
At Henry Ford Hospi ta l , all patients on dialysis (potential 
transplant recipients) or those already transplanted are 
screened month ly for cytotox ic ant ibodies to HLA antigens. 
As shown in Table V l l l , 17 of 108 dialysis patients (16%) 
demonstrated preformed ant ibodies. O n the other hand, 16 
of 57 (28%) transplanted patients w i t h funct ional kidneys 
and 11 of 17 (63%) w h o underwent nephrectomy of the 
transplanted kidney showed cytotox ic ant ibodies. 
TABLE Vlll 
CYTOTOXIC ANTIBODY SCREENING 
Patient Category 
Number of Patients 
Antibody: Positive/Tested 
Dialysis 
Functional transplanted kidney 
Nephrectomy of transplanted kidney 
% 
17/108 (16) 
16/57 (28) 
11/17 (65) 
Discussion 
The Renal Transplant Registry^" and others report that 
l iv ing related transplants have a much higher graft survival 
rate than cadaveric transplants; also, that a good HLA match 
is correlated w i t h good graft survival in the l iv ing related 
transplant. O u r results support this view. However , HLA 
identical s ib l ing transplants are not always successful. 
O p e l z and Terasaki'^ reported that in their analysis of 3,171 
related transplants HLA identical siblings demonstrated 
85% graft survival at one year regardless of whether two , 
three, or four HLA antigens were ident i f ied. They estimated 
a 15% non-HLA factor, w h i c h is the dif ference between the 
graft survival rate in transplants of these HLA identical 
siblings and identical twins. Cheigh et aP^ also po in ted out 
that genetic determinants other than HLA play an impor tant 
role in the fate of grafts. 
The questions arise whether to use a mismatched related 
kidney or a we l l matched cadaveric k idney; and if a 
mismatched related kidney is used, wha t antigen match 
w o u l d be acceptable. O u r study of l iv ing related transplants 
does not answer these questions. The graft survival rate in 
related transplants (1st and 2nd) wasext remely high because 
there was more than one haplotype match in most cases. 
Simmons et a P ' reported that the graft survival rate of 
mismatched related transplants, especial ly those w i t h more 
than one haplotype mismatch, was no better than the we l l 
matched cadeveric transplants. More recently, Cer i l l i et aP^ 
a n d C o c h r u m e t a P ' e m p h a s i z e d the importance of the MLC 
test in the l iv ing related transplant. Based on the signif icantly 
low graft survival , they warned against the use of a related 
donor w i t h a high MLC response, regardless o f t h e HLA 
match. Therefore, it is logical to use a l iv ing related kidney 
on ly when one o r m o r e HLA haplotypes match and the M L C 
response is low. 
The signif icance of HLA match ing in cadaveric k idney 
transplants has been emphasized again in the past three to 
four years. In 1974, Dausset et aP reported for the first t ime 
that the correlat ion between matched HLA antigens and 
graft survival was found to be signif icant in a series of 918 
cadaveric k idney grafts performed w i t h i n the France and 
London Transplant Group Network . The survival rate was 
34% at t w o years when there was on ly one or no matched 
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antigen; whereas the survival rate was over 70% when the 
donor and recipient were serologically indistinguishable at 
the two HLA loci. Similarly favorable results were reported 
by various centers in Europe"'^ and the United States.*"^ 
Although the numberof patients in our study was small, the 
results were better with matching HLA antigens on first 
cadaveric transplants. Fewer than two HLA mismatched 
groups demonstrated better survival rates at the one year 
follow-up. 
The greatest overall success of the cadaveric transplant 
depends on the use of a well-matched kidney, although it is 
not always possible to achieve this goal. HLA matched pairs 
are rarely encountered among unrelated donor and recip-
ient. Moreover, due tothe shortage of cadaveric kidneys, all 
available kidneys are usually transplanted, regardless of 
HLA matching. Matching can be improved, however, by 
increasing the size of the recipient pool. In Michigan, an 
organ-sharing program^"'^^ established through the Trans-
plantation Society of Michigan has been active since March 
1975. Sera for crossmatchingare collected from all potential 
recipients throughout the entire state on a monthly basis. 
Crossmatch trays are sent to each of the four participating 
histocompatibility centers. When a cadaveric donor be-
comes available, the on-call laboratory performs HLA typ-
ing and crossmatching with recipients' sera to obtain the 
best match. 
Our data as well as that of others^^ indicate there is no direct 
influence of preformed antibodies to HLA antigens on graft 
survival if the HLA crossmatch was negative at the time of 
transplant. These conflict with the report of the Renal 
Transplant Registry." However, it is essential to screen for 
cytotoxic antibody on all recipients, including dialysis 
patients and patients who suffered the loss of a transplanted 
kidney. The latter must be closely followed because two 
thirds ofthese patients (11 of 17) demonstrated antibodies 
after nephrectomy of the transplanted kidney. The screening 
should be done once a month and more frequently after the 
recipient receives blood transfusions. To avoid secondary 
immune response, the potential recipient who has positive 
antibodies at any time before transplantation should not 
receive a kidney from a donor with corresponding antigens. 
Other factors which affect graft survival, such as blood 
transfusion, age, sex, and the ABO group, have been 
reported on by many investigators."-"-^'^"'^^'^'Our data do 
not ind icate whether age, sex, and the ABO group have any 
effect on graft survival. The beneficial effect of blood 
transfusions has been emphasized recently.^'^^'' 
Recently, an additional test procedure to identify the anti-
gens on B lymphocytes was introduced."'^""^^ B lympho-
cytes possess a separate series of polymorphic antigens 
(HLA-DR) that appear to be specificities of HLA-D locus. 
Antibodies to B lymphocyte antigens are believed to play an 
important role in graft survival. Hyperacute rejection did not 
occur in patients in whom renal transplants were performed 
against a positive crossmatch to B lymphocytes but negative 
toT lymphocytes.^^''" More recently, these antibodies have 
been classified into two categories based on test tempera-
tures: 1) autoantibodies, or cold cytotoxins, which may 
enhance graft survival; and 2) alloantibodies, or warm 
cytotoxins, which were involved in graft rejection. 
Therefore, it becomes necessary to perform a crossmatch 
against B lymphocyte populations at 15°C and 37°C. Ac-
cording to Persigi et al,'^ the matching of antigens in HLA-
DR locus also promises some improvement in renal graft 
survival. 
The histocompatibility testing laboratory can contribute to 
many aspects of renal transplant. 
Donor selection 
1 Search for related donor among family members with the 
followingconsiderations: a)compatible ABO group; b)at 
least one HLA haplotype match; c) crossmatch negative; 
d)MLC negative or low reactivity; e) at least two MLC tests 
as well as family studies, including parents. 
2. If a suitable donor is not available among family mem-
bers, then proceed with the well-matched cadaveric 
transplant. 
Care of potential recipient 
1. HLAtypingon the recipient is required every six months, 
especially when all antigens are not identified. It is not 
only helpful in matching recipient and donor but also 
aids in identifying undesirable antigens in the donor. If a 
second or third donor has the same mismatched antigens 
as the previous donor, the recipient is more likely to 
develop antibodies to these antigens. This likelihood can 
be avoided by proper HLA typing of the recipient and 
donor. 
2. HLA antibody screening on a monthly basis is required 
for all transplant candidates. If a recipient demonstrates 
antibodies to HLA, the strength and specificity of anti-
bodies should be characterized. This screening pro-
cedure helps to identify an undesirable donor who has 
antigens correspond ing to the antibodies ofthe recipient. 
Typing and crossmatching B lymphocytes 
Procedures have been under investigation and are available 
on a limited basis. 
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